Primo N. Lara - Publications, H-index & Citations

Primo N. Lara

University of California, Davis

72H指数

890论文数

2.5W被引数

收录论文 126

发表时间

A Phase I trial of PLZ4-coated paclitaxel-loaded micelles in patients with refractory non–muscle-invasive bladder cancer PLZ4包被的紫杉醇负载胶束在难治性非肌层浸润性膀胱癌患者中的I期临床试验

Nanomedicine

IF3.9

2026-06-01

OAAI

Athira Narayan; Ryan C. Leibrandt; Joyce S. Lee; Marc A. Dall’Era; Jared M. Whitson; Thenappan Chandrasekar; Avery Braun; Matthew Mossanen; Hong Li; Primo N. Lara Jr; Kit S. Lam; Chong-Xian Pan; Mamta Parikh

Cancer statistics, 2026: Charting a course for a national cancer research agenda 癌症统计，2026：为国家癌症研究议程绘制蓝图

ca: a cancer journal for clinicians

IF0

2026-01-13

OAAI

Primo N. Lara Jr MD; Dawn L. Hershman MD, MS

The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)

Cancer Research Communications

IF0

2025-11-01

OAAI

Parikh, Mamta; Uboha, Nataliya V.; Takebe, Naoko; Tam, Kit; Bedard, Philippe L.; Wisinski, Kari B.; Mittra, Arjun; Yin, Ming; Yang, Yuanquan; Noonan, Anne M.; Holleran, Julianne L.; Ruel, Christopher; Frankel, Paul; Beumer, Jan H.; Newman, Edward M.; Danilov, Alexey V.; Gore, Steven D.; Lara Jr, Primo N.

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer 转录谱阐明了致死性前列腺癌中恩扎鲁他胺极端无反应的程序

npj Precision Oncology

IF8

2025-07-07

OAAI

Anbarasu Kumaraswamy; Ya-Mei Hu; Joel A. Yates; Chao Zhang; Eva Rodansky; Dhruv Khokhani; Diana Flores; Zhi Duan; Yi Zhang; Shaadi Tabatabaei; Rachel Slottke; Shangyuan Ye; Primo Lara; Adam Foye; Charles J. Ryan; David A. Quigley; Jiaoti Huang; Rahul Aggarwal; Robert E. Reiter; Max S. Wicha; Tomasz M. Beer; Matthew Rettig; Martin Gleave; Christopher P. Evans; Owen N. Witte; Joshua M. Stuart; George V. Thomas; Felix Y. Feng; Eric J. Small; Zheng Xia; Joshi J. Alumkal

Strategies for Treatment De-escalation in Metastatic Renal Cell Carcinoma 治疗降级策略在转移性肾细胞癌中的应用

European Urology Focus

IF5.6

2025-05-01

PREAI

Shuchi Gulati; Lorenzo Nardo; Primo N. Lara

A Phase 1/1B Trial of Pembrolizumab and Trametinib in Advanced NSCLC Enriched for KRAS Mutations 一项Pembrolizumab和Trametinib治疗KRAS突变富集型晚期NSCLC的I/IB期临床试验

JTO CLINICAL AND RESEARCH REPORTS

IF3.5

2025-02-01

OAAI

Riess, Jonathan W.; Lara, Matthew S.; Luxardi, Guillaume; de Rodas, Miguel Lopez; Shimoda, Michiko; Kelly, Karen; Lara, Primo N.; Beckett, Laurel; Monjazeb, Arta; Schalper, Kurt A.; Maverakis, Emanual; Gandara, David R.

POLE Mutation Associated With Microsatellite Instability and High Tumor Mutational Burden Confers Exquisite Sensitivity to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer: A Case Report and Genomic Database Analysis POLE突变与微卫星不稳定性和高肿瘤突变负荷相关，对非小细胞肺癌中免疫检查点抑制剂治疗的敏感性极高：病例报告和基因组数据库分析

CLINICAL LUNG CANCER

IF3.3

2025-01-01

PREAI

Lara, Matthew S.; Riess, Jonathan W.; Kaleka, Guneet; Borowsky, Alexander; McPherson, John D.; Godoy, Luis A.; Grego, Lorenzo; Lara Jr, Primo N.; Mitsiades, Nicholas

Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216 体重指数与转移性激素敏感性前列腺癌患者总生存期的相关性：SWOG-1216患者层面数据分析

European Urology Oncology

IF9.3

2024-11-01

PREAI

Umang Swami; Yeonjung Jo; Arshit Narang; Melissa Plets; Chadi Hage Chehade; Georges Gebrael; Shilpa Gupta; Zin Myint; Catherine Tangen; Primo N. Lara; Ian M. Thompson; Maha H.A. Hussain; Tanya B. Dorff; Seth P. Lerner; Neeraj Agarwal

Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide 3个月和7个月的前列腺特异性抗原水平可作为转移性激素敏感性前列腺癌总生存期的预后指标: SWOG S1216的结果，这是一项雄激素剥夺加Orteronel或比卡鲁胺的3期随机试验

EUROPEAN UROLOGY ONCOLOGY

IF9.3

2024-10-01

OAAI

Parikh, Mamta; Tangen, Catherine; Hussain, Maha H. A.; Gupta, Shilpa; Callis, Sam; Jo, Yeonjung; Harzstark, Andrea; Paller, Channing J.; George, Saby; Zibelman, Matthew R.; Cheng, Heather H.; Maughan, Benjamin L.; Zhang, Jingsong; Pachynski, Russell K.; Bryce, Alan H.; Lin, Daniel W.; Quinn, David I.; Lerner, Seth P.; Thompson, Ian M.; Dorff, Tanya B.; Lara, Primo N.; Agarwal, Neeraj

Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)SRD5A基因的遗传变异与前列腺癌对激素治疗的反应（SWOG S1216）

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Ingles, S. A.; Pinski, J.; Manojlovic, Z.; Xiong, S.; Weisenberger, D.; Goldkorn, A.; Tangen, C.; McConkey, D.; Lara, P. N.; Hussain, M.; Quinn, D. I.; Thompson, I. M.; Lerner, S.; Dorff, T. B.; Agarwal, N.

Phase II randomized double-blind trial of axitinib (Axi) +/- PF 04518600, an OX40 antibody (PFOX) after PD1/PDL1 antibody (IO) therapy (Tx) in metastatic renal cell carcinoma (mRCC): Final analysis II期随机双盲试验，评估阿昔替尼（Axi）联合或不含PF 04518600（一种OX40抗体，PFOX）在PD1/PDL1抗体（IO）疗法（Tx）后用于转移性肾细胞癌（mRCC）的最终分析。

ANNALS OF ONCOLOGY

IF65.4

2024-09-01

PREAI

Sadeghi, S.; Parikh, R.; Appleman, L. J.; Tsao-Wei, D.; Groshen, S.; Li, M.; Tagawa, S. T.; Nanus, D. M.; Molina, A. M.; Ornstein, M. C.; Rini, B. I.; Dreicer, R.; Quinn, D. I.; Lara, P. N.

Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial

EUROPEAN UROLOGY

IF25.2

2024-09-01

PREAI

Lara, Primo N., Jr.; Tangen, Catherine; Heath, Elisabeth I.; Gulati, Shuchi; Stein, Mark N.; Meng, Maxwell; Alva, Ajjai Shivaram; Pal, Sumanta K.; Puzanov, Igor; Clark, Joseph I.; Choueiri, Toni K.; Agarwal, Neeraj; Uzzo, Robert; Haas, Naomi B.; Synold, Timothy W.; Plets, Melissa; Vaishampayan, Ulka N.; Shuch, Brian M.; Lerner, Seth; Thompson, Ian M., Jr.; Ryan, Christopher W.

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

BMC CANCER

IF3.4

2024-07-25

OAAI

Lara Jr, Primo N.; Villanueva, Luis; Ibanez, Carolina; Erman, Mustafa; Lee, Jae Lyun; Heinrich, Daniel; Lipatov, Oleg Nikolaevich; Gedye, Craig; Gokmen, Erhan; Acevedo, Alejandro; Semenov, Andrey; Park, Se Hoon; Gafanov, Rustem Airatovich; Kose, Fatih; Jones, Mark; Du, Xiaoqi; Munteanu, Mihaela; Perini, Rodolfo; Choueiri, Toni K.; Motzer, Robert J.

Pathological concordance rate and outcomes by subtype in advanced papillary renal cell carcinoma

BJU INTERNATIONAL

IF4.4

2024-07-16

PREAI

Tripathi, Abhishek; Tangen, Catherine M.; Plets, Melissa; Li, Xiaochen; Tretiakova, Maria; Humphrey, Peter A.; Adeniran, Adebowale; Barata, Pedro C.; Gulati, Shuchi; Bergerot, Cristiane D.; Pruthi, Deepak K.; Thompson, Ian M.; Lara, Primo N.; Lerner, Seth P.; Pal, Sumanta K.; Shuch, Brian M.

Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel

PROSTATE CANCER AND PROSTATIC DISEASES

IF5.8

2024-02-29

PREAI

Lara Jr, Primo N.; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I.; LeBlanc, Michael; Thompson, Ian; Agarwal, Neeraj

Kidney Cancer, Version 2.2024 Featured Updates to the NCCN Guidelines

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK

IF16.4

2024-02-01

PREAI

Motzer, Robert J.; Jonasch, Eric; Agarwal, Neeraj; Alva, Ajjai; Bagshaw, Hilary; Baine, Michael; Beckermann, Kathryn; Carlo, Maria I.; Choueiri, Toni K.; Costello, Brian A.; Derweesh, Ithaar H.; Desai, Arpita; Ged, Yasser; George, Saby; Gore, John L.; Gunn, Andrew; Haas, Naomi; Johnson, Michael; Kapur, Payal; King, Jennifer; Kyriakopoulos, Christos; Lam, Elaine T.; Lara, Primo N.; Lau, Clayton; Lewis, Bryan; Madoff, David C.; Manley, Brandon; Michaelson, M. Dror; Mortazavi, Amir; Ponsky, Lee; Ramalingam, Sundhar; Shuch, Brian; Smith, Zachary L.; Sosman, Jeffrey; Sweis, Randy; Zibelman, Matthew; Schonfeld, Ryan; Stein, MaryElizabeth; Gurski, Lisa A.

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

EUROPEAN UROLOGY

IF25.2

2024-02-01

OAAI

Lara, Primo N.; Mayerson, Edward; Gertz, Erik; Tangen, Catherine; Goldkorn, Amir; van Loan, Marta; Hussain, Maha; Gupta, Shilpa; Zhang, Jingsong; Parikh, Mamta; Twardowski, Przemyslaw; Quinn, David I.; Leblanc, Michael; Vogelzang, Nicholas J.; Thompson, Ian; Agarwal, Neeraj

Use of recombinant microRNAs as antimetabolites to inhibit human non-small cell lung cancer

ACTA PHARMACEUTICA SINICA B

IF14.6

2023-10-01

OAAI

Chen, Yixin; Tu, Mei-Juan; Han, Fangwei; Liu, Zhenzhen; Batra, Neelu; Lara, Primo N.; Chen, Hong -Wu; Bi, Huichang; Yu, Ai -Ming

Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial

ANNALS OF ONCOLOGY

IF65.4

2023-10-01

OAAI

Lara, P. N.; Tangen, C.; Heath, E.; Stein, M.; Meng, M.; Alva, A.; Pal, S. K.; Puzanov, I.; Clark, J.; Choueiri, T. K.; Agarwal, N.; Uzzo, R.; Haas, N. B.; Plets, M.; Vaishampayan, U. N.; Shuch, B.; Thompson, I. M.; Ryan, C. W.

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial 肾细胞癌术后辅助依维莫司 (EVEREST): 一项双盲、安慰剂对照、随机、3期试验

LANCET

IF88.5

2023-09-01

OAAI

Ryan, Christopher W.; Tangen, Catherine M.; Heath, Elisabeth, I; Stein, Mark N.; Meng, Maxwell, V; Alva, Ajjai S.; Pal, Sumanta K.; Puzanov, Igor; Clark, Joseph, I; Choueiri, Toni K.; Agarwal, Neeraj; Uzzo, Robert G.; Haas, Naomi B.; Synold, Timothy W.; Plets, Melissa; Vaishampayan, Ulka N.; Shuch, Brian M.; Thompson Jr, Ian M.; Lara Jr, Primo N.

研究方向